Endothelial STING-JAK1 Axis: Mechanistic Insights into Tumor Vasculature and Immunity

Study Background and Research Question

The tumor microenvironment is a highly complex ecosystem, comprising not only malignant cells but also vasculature, immune cells, and stromal components. Vascular abnormalities in tumors—marked by chaotic architecture and poor perfusion—impede effective immune infiltration and limit the success of immunotherapies. The stimulator of interferon genes (STING) pathway has emerged as a promising immunotherapeutic target, with multiple STING agonists under preclinical and clinical investigation. Yet, the precise cellular mechanisms by which STING agonism yields antitumor effects, especially the contribution of endothelial cells, remain poorly understood (Zhang et al., 2025).

Key Innovation from the Reference Study

The reference paper by Zhang et al. delivers a critical mechanistic advance: it identifies endothelial STING as a pivotal mediator of tumor vessel normalization and effective antitumor immunity. Contrary to the prevailing view of STING as an upstream adaptor for interferon type I (IFN-I) signaling, the study demonstrates that, in endothelial cells, STING acts downstream of the interferon-α/β receptor (IFNAR), interacting directly with JAK1. This interaction, driven by IFN-I stimulation and dependent on STING palmitoylation at cysteine 91, promotes JAK1 phosphorylation and activates downstream STAT signaling. The result is normalization of tumor vasculature and enhanced infiltration of CD8+ T cells, independent of IFN-γ or CD4+ T cell involvement (Zhang et al., 2025).

Methods and Experimental Design Insights

The investigators employed a multifaceted approach combining genetic mouse models, in vitro endothelial cell assays, and analyses of human tumor specimens. Key experimental strategies included:

• Conditional knockout mice targeting STING or JAK1 specifically in endothelial cells, enabling cell-type–resolved interrogation of signaling axes.
• STING agonist administration in syngeneic tumor models to assess effects on vessel morphology, immune cell infiltration, and tumor growth.
• Protein interaction studies using immunoprecipitation and mass spectrometry to pinpoint the STING-JAK1 interaction and dissect its dependence on IFN-I stimulation and palmitoylation status.
• Immunohistochemical analyses of human melanoma tissues, correlating endothelial STING expression and palmitoylation with local CD8+ T cell infiltration.

This rigorous combination of genetic, biochemical, and histopathological tools allowed the authors to map the signaling cascade with high resolution and clinical relevance.

Core Findings and Why They Matter

The study yields several mechanistically and translationally important findings:

• Endothelial STING is essential for STING agonist–induced antitumor immunity. Tumors lacking STING in endothelial cells fail to exhibit normalized vasculature or robust CD8+ T cell infiltration after STING agonist treatment (Zhang et al., 2025).
• STING acts downstream of IFNAR in endothelial cells. Unlike in other immune cell types, STING in endothelium is not an initiator but rather a transducer of IFN-I signals, directly interacting with and activating JAK1-STAT signaling.
• STING palmitoylation at cysteine 91 is required for JAK1 interaction and signaling. Mutational analysis confirms this post-translational modification as a gating mechanism for vascular normalization and immune infiltration.
• Clinical correlation in human tumors. High endothelial STING and JAK1 expression, as well as STING palmitoylation, are associated with increased CD8+ T cell presence in human melanoma tissues, supporting translational relevance.

These findings clarify why some STING agonists may succeed or fail in the clinic—highlighting the need for compounds or regimens that effectively engage endothelial STING-JAK1 signaling for optimal immunomodulation.

Protocol Parameters

• STING agonist administration | variable (typ. 10–50 mg/kg in mice) | in vivo tumor models | To probe effects on vasculature and immune infiltration | paper
• Conditional gene knockout | cell type–specific (e.g., VE-cadherin-CreERT2) | murine models | To dissect endothelial versus other compartment effects | paper
• Immunohistochemistry for STING/JAK1/palmitoylation | antibody titrations (vendor-specific) | human/mouse tissue sections | To correlate molecular signatures with immune contexture | paper
• STING palmitoylation mutation (C88/91A) | site-directed mutagenesis | in vitro and in vivo | To test requirement for protein-protein interaction | paper
• DMXAA (Vadimezan) dosing | 25 mg/kg i.p. in mice | vascular disruption, apoptosis induction | To induce endothelial apoptosis and vessel necrosis in preclinical models | product_spec
• Apoptosis assays (caspase-3 activation) | 0.1–10 μM in vitro | tumor endothelial and NSCLC A549 cells | To quantify apoptosis induction by DMXAA | product_spec
• Workflow recommendation: Combine STING pathway readouts with apoptosis and vascular normalization markers in multiplexed assays for comprehensive tumor microenvironment analysis | workflow_recommendation

Comparison with Existing Internal Articles

Multiple internal resources have previously examined the role of DMXAA (Vadimezan) as a vascular disrupting agent and apoptosis inducer in tumor endothelial cells. For instance, this guide outlines experimental workflows for leveraging DMXAA in cancer biology, emphasizing its ability to induce apoptosis and disrupt tumor vasculature. Another article, Redefining Tumor Vasculature Disruption, discusses emerging insights into STING-JAK1 signaling and endothelial immunity, aligning closely with the mechanistic advances presented in the reference study. By situating the endothelial STING-JAK1 axis at the center of antitumor immunity and vascular normalization, Zhang et al. provide a mechanistic bridge that reinforces and extends these earlier analyses.

Limitations and Transferability

While the study provides compelling evidence for the central role of endothelial STING-JAK1 interaction, certain limitations should be noted. The reliance on murine models and genetically engineered systems may not fully recapitulate human tumor heterogeneity and microenvironmental complexity. Moreover, the study primarily focuses on melanoma and select syngeneic models; extrapolation to other tumor types, such as non-small cell lung cancer (NSCLC), should be approached with caution and validated in additional contexts (Zhang et al., 2025). Finally, while STING palmitoylation emerges as a therapeutic target, the feasibility of pharmacologically modulating this post-translational modification in vivo remains to be established.

Research Support Resources

Researchers interested in investigating tumor vascular disruption, apoptosis induction in endothelial cells, or anti-angiogenic mechanisms targeting VEGFR2 signaling can employ validated reagents such as DMXAA (Vadimezan) (SKU A8233; APExBIO). DMXAA is a well-characterized vascular disrupting agent and apoptosis inducer in tumor endothelial cells, with established protocols for use in both in vitro and in vivo cancer biology research (source: product_spec). For integration of STING pathway studies, researchers may design workflows that combine DMXAA-induced vascular disruption with immune infiltration and apoptosis assays, building on the mechanistic insights provided by the reference study (Zhang et al., 2025).